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Abstract
OBJECTIVE: To observe the protective effects of
modified Linggui Zhugan Decoction combined
with short-term very low calorie diets (VLCDs) on
cardiovascular risk factors in obese patients with
impaired glucose tolerance (IGT).
METHODS: Eighty-five obese patients with IGT of
spleen hypofunction and dampness accumulation
type were randomly divided into treated group (n=
45)and control group (n=40). The treated group
was given Linggui Zhugan Decoction combined
short-term VLCDs. The control group was given ba-
sic weight-reduction treatment. The total course
was 6 months. Changes of fasting plasma glucose
(FPG), 2-hour postprandial blood glucose (2hPG),
glycosylated hemoglobin (HbA1c), fasting insulin
(FINS), lipid metabolism, blood pressure, body
mass index (BMI) and waist circumference (WC)
were observed, and the outcomes were reviewed
after the treatment.
RESULTS: Compared with the control group, the
levels of FPG, 2hPG, HbA1c, FINS, HOMA-IR de-
creased significantly (P<0.05), and the indexes of to-
tal cholesterol (TC), triglyceride (TG), low-density li-
poprotein (LDL), systolic blood pressure (SBP), dia-
stolic blood pressure (DBP), BMI and WC were im-
proved significantly (P<0.05) in the treated group.
The transformation rate of normal glucose toler-
ance (NGT) was higher in treatment group than
control group (P<0.01). No severe adverse reaction
was found in the therapeutic course.
CONCLUSION: The modified Linggui Zhugan De-
coction combined with short-term VLCDs has good
protective effects on cardiovascular risk factors as a
treatment intervention for IGT with obesity, as it
could improve glycometabolism, significantly de-
crease the levels of blood pressure, blood lipids,
BMI, WC and effectively cut-off and reverse the de-
velopment of diabetes mellitus.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is rapidly becoming
one of the main health issues in the 21st century. Preva-
193
JTCM |www. journaltcm. com June 15, 2012 |volume 32 | Issue 2 |
Ke B et al. Effects of LGZG Decoction plus VLCDs on Cardiovascular Risk in Obese Patients with IGT
lence has increased explosively in the last two decades,
and global estimates indicate a further rise from a cur-
rent 150 million people with diabetes, to 300 million
in 2025[1]. Almost 90% of T2DM patients are over-
weight or obese[2]. Impaired glucose tolerance (IGT) is
a category of glucose tolerance, as an intermediate cate-
gory between normal glucose tolerance and diabetes.
About 5% of IGT patients will develop into T2DM pa-
tients every year[3].The most important modifiable risk
factor for progression from IGT to diabetes is obesi-
ty. Lifestyle intervention can reduce the incidence of
IGT[4]. Studies have shown that very low calorie diets
(VLCDs) is a safe and effective strategy to treat some
metabolic related diseases[5]. There are many potential
benefits for VLCDs in preventing cardiovascular risk
factors, such as body weight, glycaemic control, blood
pressure and lipid profile[6-10]. Traditional Chinese medi-
cine (TCM) has its unique advantages in preventing
these diseases. But, the literature about how to treat
obese patients with IGT by Chinese medicine com-
bined with VLCDs is rare. In the present study, we
aimed to explore the effectiveness of Linggui Zhugan
Decoction combined with VLCDs in treatment of
obese patients with IGT, to find out the underlying
mechanisms. This study was approved by the appropri-
ate ethics committees and was performed in accor-
dance with the ethical standards laid down in the Dec-
laration of Helsinki. All persons signed their informed
consent prior to their inclusion in the study.
METHODS
Diagnostic criteria
IGT was diagnosed referring to the Diagnosis and Clas-
sification of Diabetes Mellitus by World Health Orga-
nization (1999)[11], i.e. the 2h post-prandial plasma glu-
cose (2hPG) ≥7.8 mmol/L (140mg/dL), but<11.1
mmol/L (200 mg/dL). Obesity was diagnosed referring
to Overweight and Obesity Prevention and Control
Guideline for Chinese Adult (Draft), published in
2003, i.e[12]. body mass index (BMI) >25 kg/m2. The
Chinese medicine syndrome patterns of the patients
were differentiated, according to the Guiding Princi-
ples for Clinical Research on New Drugs of TCM[13],
and those with syndrome pattern of spleen hypofunc-
tion and dampness accumulation type were included in
this study.
Inclusive criteria
Patients matching the following criteria were included:
1) with diagnosis satisfying IGT and obesity; 2) aged
between 25-70 years; 3) had never received any therapy
for IGT before; 4) agreed to participate in the trial.
Exclusive criteria
Patients in the following conditions were excluded: 1)
with any cardiocerebral vascular events occurring in
the last 6 months; 2) with a stressed manner or second-
ary hyperglycemia; 3) complicated with endocrinal dis-
eases or primary diseases other than diabetes mellitus
(DM); 4) complicated with severe primary diseases of
liver, kidney, endocrine systems, or hemopoietic sys-
tem, or with other severe diseases, such as malignant tu-
mor, grave malnutrition, mental disorders, etc; 5) with
advanced hypertension of or over the 3rd grade; 6) tak-
ing other hypoglycemic agents simultaneously; 7) the
women in pregnant or lactation stage, or the patients
of allergic constitution or with multiple drug hypersen-
sitivity; 8) incapable to cooperate in the trial, by taking
or removing the designated drugs without doctor's ad-
vices, or asking for the possibility quitting in the mid-
way of the trial.
General materials
Eighty five obese patients with IGT hospitalized at Tra-
ditional Chinese Medicine Department, First Affiliated
Hospital of Sun Yat-Sen University (FAHSYSU) from
June 2009 to March 2011 were enrolled in this study.
All patients took part in this research approved by the
Scientific Research Section, FAHSYSU and the Moral
and Ethical Committee, FAHSYSU, following the ac-
quisition of informed consent. The patients were ran-
domly assigned to the treated group (n=45) and con-
trol group (n=40) with a random number table. The
two groups were no significant difference in gender,
age, course of disease, BMI, blood pressure (systolic
and diastolic), blood glucose (FPG and 2hPG), and
blood lipids (P>0.05, Table 1). General data of pa-
tients are listed in table 1.
Table 1 Baseline data of patients ( xˉ ±s)
Items
Case(M/F)
Age(Year)
Course
BMI(Kg/m2)
SBP(mmHg)
DBP(mmHg)
FPG(mmol/L)
2hPG(mmol/L)
HbA1C (%)
FINS(mmol/L)
TC(mmol/L)
TG(mmol/L)
Control
40(20/20)
45.7±7.5
3.8 ± 2.6
28.5±3.7
149.3±4.8
91.2±6.9
6.71±0.29
9.56±1.58
6.35±1.27
18.45±8.36
6.08±0.88
3.49±2.55
Treated
45(23/22)
46.5±7.3
3.5 ± 2.4
28.7±3.4
147.4±5.1
92.5±7.2
6.68±0.32
9.43±1.62
6.46±1.24
18.38±8.41
6.12±0.83
3.34±2.51
Notes: BMI=body mass index; SBP=systolic blood pressure;
DBP=diastolic blood pressure; fasting plasma glucose; 2hPG=
2-hour postprandial blood glucos; HbA1C=glycosylated
hemoglobin; FINS=fasting insulin; TC=total cholesterol; TG=
triglyceride.
Treatment
The control group was given therapeutic prescription
of special diets and exercise for losing weight. The pre-
scription of diets included: 1) The daily energy require-
ment was determined; 2) The distribution of three ma-
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jor nutrients: carbohydrates (50%-60%), protein≤30% ,
high-fiber diet; 3) The proportions of three meals a day
are 2/5, 2/5, 1/5. The recipe was developed by the Nu-
trition Department in the First Affiliated Hospital of
Sun Yat-Sen University. The prescription of exercise
was aerobic exercise, including brisk walking, swim-
ming, jogging, dancing, etc. The training lasted 60
minutes each time, three times a week, and one month
was a course. The total course of treatment was six
months.
The treated group was given intervention of modified
Linggui Zhugan Decoction combined with short-term
VLCDs. The treatment fell into three phases: pre-treat-
ment preparation phase, VLCDs phase and convales-
cence phase. The treatment was preceded by 1-3 relief
days to decrease food ingestion gradually from the nor-
mal level, 2/3 of the normal to 1/3 of the normal. If
the patients felt hungry, we recommended they supple-
mented with fruits or vegetables. Only fruits were tak-
en on the day they were admitted in hospital. A 5-day
VLCDs phase then began. 10-20g of thenardite pow-
der was used to clean bowel first. After then modified
Linggui Zhugan Decoction was oral administered
twice a day. The decoction included Chinese herbal
medicine of Fu Ling (Poria), Gui Zhi (Ramulus Cinna-
momi), Bai Zhu (Radix Atractylodis Macrocephalae),
Gan Cao (Radix Glycyrrhizae), Dang Shen (Radix Co-
donopsis) and Da Huang ( Radix et Rhizome Rhei) to
warm and dissipate phlegm as well as strengthen
Spleen and remove turbidity. All of the herbs were pro-
vided by the pharmacy of the First Affiliated Hospital
of Sun Yat-Sen University. Patients took the Decoction
continually for a month. Meantime, they were recom-
mended to sip millet soup, which was boiled with less
than 150 g millet to 1000 mL water, along with drink-
ing another 3 L of mineral water. Patients also could
choose to drink moderate quantities of sports beverag-
es to maintain electrolyte balance. But solid food was
refrained at the phase. For breaking the treatment, pa-
tients reintroduced food stepwise following the meth-
ods of increasing food amount gradually, changing in-
gestion of fluid diet into solid food slowly, and tasting
lite food into the normal flavor, which lasted at least 3
days. After the treatment, participants received sugges-
tions on healthy diets habit and exercises. This therapy
was carried out every two months. The patients should
complete three times throughout the course of treat-
ment.
Indexes of observation
The indexes for safely treatment monitoring were those
for routine blood test, liver and kidney function, which
were recorded to estimate adverse reactions in the thera-
peutic period. The indexes for efficacy observation
were HbA1c, FINS, FPG, 2hPG through a Standard
75 g oral glucose tolerance test (OGTT) and Homeo-
static Model Assessment of Insulin Resistance
(HOMA-IR) calculated by (HOMA-IR=FPG × FINS/
22.5); SBP, DBP, BMI, waist circumference (WC), To-
tal cholesterol (TC), triglyceride (TG), low density li-
poprotein cholesterol (LDL), high density lipoprotein
cholesterol (HDL) were also checked.
Statistical analysis
Data are presented as mean ±standard deviation ( xˉ ±s).
Data analyses were performed using SPSS for Win-
dows version 16.0 (SPSS Inc., Chicago, IL, USA). Da-
ta collected before and after treatment were compared
using paired-sample t test, and the comparison of the
IGT therapeutic result between the two groups was
done by Chi-square test. A P-value of <0.05 was con-
sidered to be statistically significant.
RESULTS
By the end of the observation, 4 patients out of all the
85 had dropped out from the follow-up, among them
2 in the control were due to change of address and the
other 2 in the treated group withdrew for personal rea-
sons.
Comparisons of blood glucose, FINS, HOMA-IR and
HbA1C
After 6 months of treatment, the levels of FPG, 2hPG,
FINS, HOMA-IR and HbA1C were significantly de-
creased in the two groups, but were significantly low-
ered in the treated group (P<0.05), and comparisons
of the indexes between groups showed a significant dif-
ference (P<0.05, Table 2)
Comparisons of blood lipids
The levels of TC, TG, and LDL were significantly
changed after 6 months of treatment in the two group,
but were significantly lowered in the treated group(P<
0.05), and comparisons of these indexes between
groups showed a significant difference (P<0.05, Table
3).
Comparisons of blood pressure, BMI and WC
After 6 months of treatment, the levels of SBP, DBP,
BMI and WC were changed significantly (P<0.05) in
the two group. However, in the treated group, SBP,
DBP, BMI and WC were lowered significantly after
treatment (P<0.05, Table 4)
Comparison of glucose tolerance results
After 6 months of treatment, 10 patients out of the 38
in the control group had their glucose tolerance re-
versed to normal, accounting for 26.3%, 17 (44.7%)
remained in IGT, and 11(28.9% ) turned into DM.
While of the 43 patients in the treated group 28
(65.1%) had tolerance reversed, 12 (27.9%) remained
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in IGT and 3(6.9%) turned into DM. The results in the
two groups were significantly different (P<0.01, Table 5)
Adverse reaction
Results of routine blood, liver and kidney function in
both groups examined before and after treatment were
all in the normal range. There were five patients in the
treated group that felt fatigue, hunger and dizziness,
and which was recovered after giving normal diets. Be-
sides, no serious side effect was found in the two
groups.
Table 2 Comparisons of blood glucose, FINS and HbA1 between two groups ( xˉ ±s)
Group
Control
Treated
Time
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment
Case
40
38
45
43
FPG (mmol/L)
6.71±0.29
6.35±0.20*
6.68±0.32
5.41±0.47*Δ
2hPG (mmol/L)
9.56±1.58
8.43±1.07*
9.43±1.62
6.91±0.72*Δ
FINS (mU/L)
18.45±8.36
17.44±5.28*
18.38±8.41
15.36±3.84*Δ
HOMA-IR
4.2±1.8
3.2±0.6*
4.1±1.7
2.2±0.9*Δ
HbA1c (%)
6.35±1.27
6.24±0.84*
6.46±1.24
6.12±0.57*Δ
Notes: *P<0.05 , compared with pre-treatment in the same group; ΔP<0.05, compared with the control group post-treatment.
Table 3 Comparisons of blood lipids between two groups ( xˉ ±s)
Group
Control
Treated
Time
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment
Case
40
38
45
43
TC(mmol/L)
6.08±0.88
5.62±0.62＊
6.12±0.83
5.31±0.42＊Δ
TG (mmol/L)
3.49±2.55
2.41±1.84＊
3.34±2.51
2.18±1.32＊Δ
LDL (mmol/L)
3.78±1.06
2.78±0.74＊
3.69±1.08
2.35±0.52＊Δ
HDL(mmol/L)
1.14±0.29
1.19±0.32
1.13±0.27
1.22±0.34
Notes: *P<0.05, compared with pre-treatment in the same group; ΔP<0.05, compared with the control group post-treatment.
Table 4 Comparisons of blood pressure, BMI, WC between two groups ( xˉ ±s)
Group
Control
Treated
Time
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment
Case
40
38
45
43
SBP(mmHg)
149.3±4.8
139.2±6.7*
147.4±5.1
135.3±3.2*△
DBP(mmHg)
91.2±6.9
86.4±4.9*
92.5±7.2
82.3±3.5*△
BMI (Kg/m2)
28.5±3.7
26.7±2.6*
28.7±3.4
25.0±1.8*△
WC(cm)
91.37±6.76
86.94±4.80*
91.21±7.07
83.76±3.45*△
Notes: *P<0.05, compared with pre-treatment in the same group; △P<0.05, compared with the control group post-treatment.
Table 5 Comparison of glucose tolerance results between two groups (Case%)
Group
Control
Treated
Case
38
43
NGT
10 (26.3%)
28 (65.1%)*
IGT
17(44.7%)
12(27.9%)
DM
11(28.9%)
3(6.9%)*
Note: *P<0.01, compared with the control.
DISCUSSION
From with normal glucose tolerance to in the clinical
course of diabetes, diabetes patients must go through a
stage of impaired glucose tolerance (IGT). IGT was
now generally accepted as pre-diabetes phase, which
can develop into a dangerous phase of diabetes. Studies
have shown that up to 72.79% of overweight or obese
patients were complicated by IGT[14].
Therefore, it is significant for overweight or obese pa-
tients with IGT to prevent the progress developing the
stage of diabetes by early diet, exercise and other life-
style interventions as soon as possible.
Very-low-calorie diets (VLCDs) are defined as diets
limiting energy intake to 450-800 kcal per day while
providing at least 50g of high-quality protein and ami-
no acids, essential fatty acids and daily requirements of
trace elements, vitamins and minerals [15-17]. They are
recommended only to the obese (BMI≥30 kg/m2) in
United States and Europe. Many studies have shown
that VLCDs can produce multiple beneficial effects on
blood glucose, blood pressure and lipid regulation in
patients with T2DM by virtue of both calorie restric-
tion and weight loss[18-21].
However, the constitution of Chinese people is signifi-
cantly different from European's. We found that many
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patients cannot fully accept the traditional VLCDs. Ac-
cording to the experiences from our clinical practice,
we modified European VLCDs and introduce TCM to
meet the need for Chinese better. The Yellow Emper-
or's Inner Classic (Huangdi Neijing) is the most impor-
tant ancient text in Chinese medicine as well as a ma-
jor book of Daoist theory and lifestyle. In this book,
the preventive thought of dietary restraint and preven-
tive treatment of diseases was advanced. So, the theoret-
ical basis of VLCDs can be traced back to the Yellow
Emperor's Inner Classic. According to traditional Chi-
nese medicine, obesity and IGT should attribute to the
categories of "turbid phlegm" and "diabetes". Insuffi-
cient natural endowment, excessive eating and drink-
ing, too much fat food, little exercise, and psychologi-
cal stress are the main reasons for pre-diabetes. The ba-
sic pathogenesis of the disorder is dysfunction of liver,
spleen and kidney. Mind dissatisfaction and long-term
excessive eating can lead to dysfunction of depression
of liver-Qi, spleen in transport and aggregation of
phlegmatic hygrosis. Therefore, when it comes to treat-
ment, we should regulate Qi, strengthen spleen, dis-
solve dampness and dissipate phlegm[22].
Patients have no outside food intake in VLCDs period.
According to the theories of traditional Chinese medi-
cine, reducing the burden of spleen and stomach, the
spleen can effectively transport moisture, so that Chi-
nese herbs in the body are quickly absorbed. Linggui
Zhugan Decoction, originated from "Treatise on Fe-
brile Diseases" is a recipe of warming yang and dissipat-
ing excessive fluid. Modified Linggui Zhugan Decoc-
tion contains Fu Ling ( Poria), Gui Zhi (Ramulus Cin-
namomi), Bai Zhu (Radix Atractylodis Macrocepha-
lae), Gan Cao (Radix Glycyrrhizae), Dang Shen (Radix
Codonopsis), Da Huang (Radix et Rhizome Rhei) and
other components. Bai Zhu, Dang Shen and Gan Cao
can nourish Qi to invigorate spleen; Fu Ling can
strengthen spleen and induce diuresis; Gui Zhi can
warm yang and fluidize Qi; Da Huang can clean up
the stomach and intestine. All herbs were played a role
of warming yang, dissipating excessive fluid and
strengthening spleen.
It showed that compared with the control group, FPG,
2hPG, FINS, HOMA-IR, blood lipids (TC, TG,
LDL), BMI , WC, blood pressure (SBP, DBP) in treat-
ment group significantly decreased after treatment.
Short-term VLCDs combined Linggui Zhugan Decoc-
tion can positively regulate blood glucose in obese pa-
tients with IGT primarily by accelerating the mobiliza-
tion of body fat, preventing fat accumulation and in-
creasing the body sensitivity to insulin. Thus, blood
sugar in obese patients with IGT returne to normal lev-
els. This therapy has played a good protection on car-
diovascular risk factors. Also it proved that this therapy
is a safe and effective treatment. Accordingly, if it is dif-
ficult to achieve a satisfied effect after a healthy diet
and exercise for those obese patients with IGT,
short-term VLCDs combined Linggui Zhugan Decoc-
tion should be a good strategy. The long-term effects of
VLCDs on glycaemic control, cardiovascular risk and
diabetic complications are generally small or absent,
and there are no data on the long-term effects on com-
plications and mortality[23]. Therefore, further studies
are needed to proof the long-term effects of VLCDs
combined Linggui Zhugan Decoction.
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